Sort
48,018 grants matching “immunotherapy”
Improving IL12 Immunogene Therapy for Glioblastoma Based on Human Clinical Trial Results
$633,656E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2025 · NS
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics
$633,648Stylianos Bournazos · Rockefeller University · R01 · FY2020 · CA
Defining the β-catenin/CBP-catenin/CBP axis in head and neck cancer
$633,640Maria A Kukuruzinska · Boston University Medical Campus · R01 · FY2024 · DE
Uncovering the metabolic underpinnings of T cell exhaustion
$633,550Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AI
Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer
$633,538Stacey Deleria Finley · University Of Southern California · U01 · FY2018 · CA
Metabolic impact on T cell-mediated cancer immunity and therapy
$633,500Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2022 · CA
Enhancing Pathogen-Specific Memory CD8+ T cell Responses In Vivo
$633,454Gregoire Stephane Lauvau · Albert Einstein College Of Medicine · R56 · FY2024 · AI
Metabolic impact on T cell-mediated cancer immunity and therapy
$633,444Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Role of the Innate Immune System in the Survival of Auditory Neurons
$633,415Mark E. Warchol · Washington University · R01 · FY2017 · DC
Population Modeling of Bladder Cancer Detection and Control
$633,411Thomas Trikalinos · Brown University · U01 · FY2024 · CA
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
$633,409Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2025 · CA
Sustaining antitumor effector CD8+ T cells for cancer therapy
$633,355Bin Zhang · Northwestern University At Chicago · R01 · FY2024 · CA
Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis
$633,251Andrea Schietinger · Sloan-Kettering Inst Can Research · U54 · FY2020 · CA
Clinical trials employing cancer vaccine combination therapies
$633,201James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines
$633,201James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Impact of mutation burden on cancer growth and the immune landscape
$633,201Shridar Ganesan · Rbhs -Cancer Institute Of New Jersey · R01 · FY2022 · CA
Targeting Tryptophan Metabolism in Rectal Cancer
$633,106Matthew Aaron Ciorba · Washington University · R01 · FY2024 · CA
Mechanism of Pathologic Tau Fibrils Neuron-to-Neuron Transmission and Neuroinflammation in Alzheimer's Disease
$633,002Xiaobo Mao · Johns Hopkins University · R01 · FY2024 · AG
Mechanism of Pathologic Tau Fibrils Neuron-to-Neuron Transmission and Neuroinflammation in Alzheimer's Disease
$633,002Xiaobo Mao · Johns Hopkins University · R01 · FY2023 · AG
Mechanism of Pathologic Tau Fibrils Neuron-to-Neuron Transmission and Neuroinflammation in Alzheimer's Disease
$633,002Xiaobo Mao · Johns Hopkins University · R01 · FY2022 · AG
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma
$632,932Arash Ash Alizadeh · Stanford University · U01 · FY2018 · CA
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER
$632,900Michael T Lewis · Baylor College Of Medicine · U24 · FY2020 · CA
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER
$632,898Michael T Lewis · Baylor College Of Medicine · U24 · FY2021 · CA
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
$632,873Elias Sayour · University Of Florida · R37 · FY2025 · CA
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomes
$632,860Brock Clarke Christensen · Dartmouth College · R01 · FY2017 · CA